Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00798538 · ClinicalTrials.gov registry record · Phase 4
Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)
A Phase 4 study of HIV and Substance-Related Disorders, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00798538: Completed Phase 4 study of HIV and Substance-Related Disorders, sponsored by Yale University.
NCT00798538 is a Phase 4 study of HIV and Substance-Related Disorders that has completed, run by Yale University. The registered enrollment target is 60 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00798538, a Phase 4 study of HIV and Substance-Related Disorders, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the feasibility, cost and effectiveness of interventions designed to integrate buprenorphine treatment for opioid dependence into HIV primary care in ten HIV care centers in the U.S. In the site led by Dr. Altice, we compare two models of providing HIV care and buprenorphine treatment. Assignments are based on participants' city of residence. In the onsite (integrated care) model, participants receive buprenorphine, substance abuse counseling and HIV care at one location: the Waterbury Hospital Infectious Disease Clinic. In the off-site model (non-integrated care) buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively. Data is collected from interviews with participants, reviews of medical records, and surveys and interviews with clinicians.
Conditions Studied
Interventions
- OTHER Services will be provided at one site
- OTHER Services remain dispersed; i.e., not centralized to one-location or provider.
Study Locations (1)
Connecticut
- Yale AIDS Program - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-08 |
| Est. Completion | 2010-08 |
| Phase | Phase 4 |
What the finished NCT00798538 record still lists
NCT00798538 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (86% lower).
The record links to 10 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Services will be provided at one site is the first listed.
NCT00798538 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00798538 about?
NCT00798538 is a clinical study titled "Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)". The purpose of this study is to assess the feasibility, cost and effectiveness of interventions designed to integrate buprenorphine treatment for opioid dependence into HIV primary care in ten HIV care centers in the U.S. In the site led by Dr. Altice, we compare two models of providing HIV care an...
What is the current status of trial NCT00798538?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2005-08. Estimated completion is 2010-08.
What conditions does trial NCT00798538 study?
This clinical trial studies the following conditions: HIV, Substance-Related Disorders, Substance Abuse, Drug Abuse, Drug Addiction.
What interventions are being tested in trial NCT00798538?
The interventions under investigation include: Services will be provided at one site (OTHER), Services remain dispersed; i.e., not centralized to one-location or provider. (OTHER).
Who is sponsoring clinical trial NCT00798538?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00798538 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00798538's enrollment target sits among peer trials
60 200th of 303 higher than 100 of 303 other HIV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
RECRUITING · Phase 4
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
RECRUITING · Phase 4
-
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
-
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia